Veru Inc reports results for the quarter ended in March - Earnings Summary
Brief: Veru Reports Fiscal 2023 Q2 Financial Results
Brief: Veru Q2 revenue USD 6.6 million
Veru Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Veru Reaches Agreement With FDA On Confirmatory Phase 3 Clinical Trial
Brief: Veru Inc Files For Offering Of Up To $100 Million Of Shares Of Common Stock
Brief: Veru Enters Into Common Stock Purchase Agreement For Up To $100 Million With Lincoln Park Capital
Veru rises on sale of prostrate disorder drug business
Brief: Veru Sells Entadfi Business For $20 Million Plus Up To An Additional $80 Million From Sales Milestones
Brief: Veru Enters Into Supply Agreement With Afaxys To Expand Access To Fc2 Female Condom® In U.S. Public Health Sector
Brief: Veru Inc Entered Into Stock Purchase Agreement With Frost Gamma Investments Trust
Veru up on positive poxviruses therapy data from preclinical study
Brief: Veru Announces Preclinical Study Results That Demonstrate Sabizabulin Inhibits Poxviruses
U.S. STOCKS ON THE MOVE-AMC Entertainment, Trilogy Metals, Nogin
U.S. STOCKS ON THE MOVE-Duckhorn Portfolio, BullFrog AI, VBI Vaccines
Veru gains on positive data for respiratory disease drug in animal study
Brief: Veru Inc Files For Mixed Shelf Of Up To $200 Mln
U.S. STOCKS ON THE MOVE-Jack Henry, Coty, Netflix
U.S. STOCKS ON THE MOVE-Boeing, Alcoa, Canadian Pacific